Most read articles by the same author(s)
- Claudio Jommi, Giovanni Apolone, Giovanna Scroccaro, Valentina Acciai, Antonio Addis, Andrea Ardizzoni, Renato Bernardini, Alberto Bortolami, Alessia Brigido, Giuliano Buzzetti, Pier Luigi Canonico, Francesca Caprari, Stefano Centanni, Chiara Cernetti, Americo Cicchetti, Giorgio Corsico, Francesco Damele, Filippo De Braud, Sara Manurita, Francesco Saverio Mennini, Irene Olivi, Federica Parretta, Lara Pippo, Stefania Pulimeno, Massimo Riccaboni, Giuseppe Rossi, Cecilia Saleri, Alessandra Sinibaldi, Federico Spandonaro, Cristian Stefenoni, Elena Visentin, Pierluigi Viale, Giuseppina Zapparelli, Patrizia Popoli, Drugs price and reimbursement regulation: comparators, endpoints and role of the cost-effectiveness , Global and Regional Health Technology Assessment: Vol. 9 No. 1 (2022): January-December 2022
- Claudio Jommi, Michela Meregaglia, Carmine Pinto, Unmet need: definitions, literature evidence and implications for HTA , Global and Regional Health Technology Assessment: Vol. 10 No. 1 (2023): January-December 2023
- Patrizia Popoli, Giovanni Giuliani, Arturo Cavaliere, Claudio Jommi, Early access programs for medicines: a reform proposal for the Italian National Health Service , Global and Regional Health Technology Assessment: Vol. 11 No. 1: January-December 2024
- Claudio Jommi, Francesca Patarnello, Cosetta Bianchi, Giuliano Buzzetti, Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panel , Global and Regional Health Technology Assessment: Vol. 11 No. 1: January-December 2024
- Dario Lidonnici, Virginia Ronco, Martina Isernia, Elena Lanati, Claudio Jommi, Pier Luigi Canonico, Armando A. Genazzani, Access times to medicines in Italy in the period 2015-2017: Analysis of the evaluation times of the Italian Medicines Agency , Global and Regional Health Technology Assessment: Vol. 5 No. 1 (2018): January-December 2018
- Arianna Bertolani, Giovanni Fattore, Fabrizio Pregliasco, The hospitalization burden of influenza: just the tip of the iceberg? , Global and Regional Health Technology Assessment: Vol. 5 No. 1 (2018): January-December 2018
- Claudio Jommi, Marianna Cavazza, Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals , Global and Regional Health Technology Assessment: Vol. 6 No. 1 (2019): January-December 2019
- Carlo Lucioni, Claudio Jommi, Value of health technologies, HTA and decisions , Global and Regional Health Technology Assessment: Vol. 4 No. 1 (2017): January-December 2017
- Claudio Jommi, Innovation and Drugs Price and Reimbursement: A Comparison between Italy and the other Major EU Countries , Global and Regional Health Technology Assessment: Vol. 2 No. 3 (2015): September-December 2015
- Claudio Jommi, Francesco S. Mennini, Pier L. Canonico, Paolo Bruzzi, Immuno-Therapy in the Treatment of Cancer: Implications for Efficacy and Economic Evaluations , Global and Regional Health Technology Assessment: Vol. 3 No. 1 (2016): January-April 2016